Subscribe to Search results

Peter Hamilton outlined his intention to make a special clinical study of the problems of liver disease in haemophiliacs

Published on:

Dr Jones asked that everyone who used commercial concentrate record full batch details whenever it was used in the region and that he be notified of cases of jaundice

Published on:

In a confidential note, Dr Jones stated that an association between commercial concentrates and hepatitis had been proven. In Newcastle there had been 16 cases of jaundice over the past 18 months, of whom 15 had received commercial concentrate and 10 had been on home therapy.

Published on:

Dr Jones noted in a publication that all concentrates prepared from large donor pools carry a greater risk of serum hepatitis and possibly other disease transmission than cryoprecipitate. They should therefore be reserved for the treatment of severe haemophilia A in older children and adults.

Published on:

Dr Jones was critical of the World in Action documentary outlining that it presented a dramatised account of the danger of hepatitis which, by being taken out of context

Published on:

Newsletter from the Haemophilia Society Northern Branch illustrated the risks of jaundice, hepatitis B and hepatitis and made reference to concerns over large plasma pools and suggested that the associated dangers were not as much of a priority or concern for those responsible for the finance, organisation and development of these voluntary organisations, and by some members of the medical profession who continued to advocate the use of whole blood

Published on:

Dr Jones stated in a publication on home therapy that "The substantial improvements in the quality of life ... may be bought at the expense of shorter survival."

Published on:

The haemophilia centre at Cardiff moved in 1971 from Cardiff Royal Infirmary to University Hospital Wales

Published on:

In late 1972, Professor Bloom described the local supply of cryoprecipitate as "quite good", however that he would prefer to use freeze-dried concentrate if available.

Published on:

In 1976, Professor Bloom explained that while Cardiff used cryoprecipitate for ordinary bleeds, they needed freeze-dried material for the treatment of inhibitors and for home treatment.

Published on:

When considering Factor 8 supply, Professor Bloom had stopped using Armor product due to the hepatitis problem and he also no longer bought Immuno because the price was too high.

Published on:

Annual return from 1976 displaying the results of the treatment of Haemophilia A in Cardiff through the use of substantial quantities of cryoprecipitate, very modest amount of NHS concentrate, significant amounts of Kryobulin and Hemofil, as well as the use of small amounts of Factorate, Profilate and Koate.

Published on:

Annual return from 1977 showing that cryoprecipitate was used twice as much as commercial concentrate (primarily Hemofil) than NHS concentrate was used in Cardiff.

Published on:

Annual return regarding Cardiff Haemophilia Centre from 1978 showing that cryoprecipitate was used twice as much as commercial concentrate. Factorate was the largest in volume as well as substantial quantities of Koate and Hemofil also used.

Published on:

Annual return from 1979 showing that significant cryoprecipitate were still in use in the Cardiff Haemophilia Centre, but that over a million units of commercial concentrate was in use, compared with 328,538 units of NHS concentrate.

Published on:

In relation to the risks of hepatitis, Professor Bloom described to another clinician that a small percentage of these freeze dried preparations contained unavoidably the virus of serum hepatitis and therefore were potentially dangerous to the patient and their relatives.

Published on:

Inquiry updates timetable and opens registration for September hearings

Published on:

Professor Bloom held that during the 1970s that although most patients were infected with NANB Hepatitis, patients did not suffer from clinical liver disease.

Published on:

Professor Bloom held that during the 1980s most haemophilia specialists recognised the risk of hepatitis in haemophiliacs after treatment with concentrates, however the general belief was that bleeding was still the primary cause of death amongst patients.

Published on:

Professor Bloom stated that by 1 January 1985, all Haemophilia Centres should have received the AIDS advisory document.

Published on: